Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

International Journal of Pharmaceutics

Volumn 372, Issue 1-2, 2009, Pages 76-84

  Wasan, Ellen K ^a,b,c   Bartlett, Karen ^b   Gershkovich, Pavel ^b   Sivak, Olena ^b   Banno, Brian ^b   Wong, Zhao ^c   Gagnon, Jeffrey ^c   Gates, Byron ^d   Leon, Carlos G ^b   Wasan, Kishor M ^b  

^a BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Amphotericin B; Antifungal activity; Aspergillus fumigatus; Candida albicans; Lipid excipients; Lipid based drug delivery; Oral formulation; Self emulsifying drug delivery systems

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; FATTY ACID; GALACTOMANNAN; GLYCEROL OLEATE; MACROGOL; MACROGOL 2000; MACROGOL 750; SURFACTANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD LEVEL; CANDIDA ALBICANS; COLONY FORMING UNIT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ANALYSIS; DRUG DEVELOPMENT; DRUG SOLUBILITY; DRUG STABILITY; HISTOPATHOLOGY; MALE; MISCIBILITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HUMANS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 64149117052     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.01.003     Document Type: Article

References (17)

1. Esposito E., Bortolotti F., Menegatti E., and Cortesi R. Amphiphilic association systems for Amphotericin B delivery. Int. J. Pharm. 260 (2003) 249-260
2. Forster D., Washington C., and Davis S.S. Toxicity of solubilized and colloidal Amphotericin B formulations to human erythrocytes. J. Pharm. Pharmacol. 40 (1988) 325-328
3. Gershanik T., and Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50 (2000) 179-188
4. Gursoy R.N., and Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58 (2004) 173-182
5. Lavasanifar A., Samuel J., and Kwon G.S. Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate l-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of Amphotericin B. J. Control. Rel. 77 (2001) 155-160
6. Rajagopalan N., Dicken C.M., Ravin L.J., and Sternson L.A. A study of the solubility of Amphotericin B in nonaqueous solvent systems. J. Parenter. Sci. Technol. 42 (1988) 97-102
7. Risovic V., Sachs-Barrable K., Boyd M., and Wasan K.M. Potential mechanisms by which Peceol increases the gastrointestinal absorption of Amphotericin B. Drug Dev. Ind. Pharm. 30 (2004) 767-774
8. Risovic V., Rosland M., Sivak O., Wasan K.M., and Bartlett K. Assessing the antifungal activity of a new oral lipid-based Amphotericin B formulation following administration to rats infected with Aspergillus fumigatus. Drug. Dev. Ind. Pharm. 33 (2007) 703-707
9. Sachs-Barrable K., Thamboo A., Lee S.D., and Wasan K.M. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J. Pharm. Pharm. Sci. 10 (2007) 319-331
10. Sachs-Barrable K., Lee S.D., Wasan E.K., Thornton S.J., and Wasan K.M. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral Amphotericin B formulation for the treatment of systemic fungal infections. Adv. Drug Deliv. Rev. 60 (2008) 692-701
11. Sánchez-Brunete J.A., Dea M.A., Rama S., Bolás F., Alunda J.M., Torrado-Santiago S., and Torrado J.J. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J. Drug Target. 12 (2004) 453-460
12. ®) in combination with Caspofungin in experimental systemic aspergillosis. J. Pharm. Sci. 93 (2004) 1382-1389
13. Tancrède P., Barwicz J., Jutras S., and Gruda I. The effect of surfactants on the aggregation state of Amphotericin B. Biochim. Biophys. Acta 1030 (1990) 289-295
14. Tiyaboonchai W., Woiszwillo J., and Middaugh C.R. Formulation and characterization of Amphotericin B-polyethylenimine-dextran sulfate nanoparticles. J. Pharm. Sci. 90 (2001) 902-914
15. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., and Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 56 (2004) 453-462
16. Yu B.G., Okano T., Kataoka K., Sardari S., and Kwon G.S. In vitro dissociation of antifungal efficacy and toxicity for Amphotericin B-loaded poly(ethylene oxide)-block-poly(beta benzyl l aspartate) micelles. J. Control. Rel. 56 (1998) 285-291
17. Wasan K.M., Vadiei K., Lopez-Berestein G., and Luke D.R. Pharmacokinetics, tissue distribution and toxicity of free and liposomal Amphotericin B in diabetic rats. J. Infect. Dis. 161 (1990) 562-566